Consolidated Statements of Income (Loss) (unaudited)

(thousands of U.S. dollars, except number of common shares and per share amounts)

| | Three Months Ended | | | Nine Months Ended | | |
|---|--------------------|----------------|-------------------------|--------------------|-------------------------|--|
| | | Sep 30 2016 | Sep 30 2015 | Sep 30 2016 | Sep 30 2015 | |
| Revenue | \$ | 510,094 \$ | 527,000 | \$ 1,412,840 \$ | 1,741,538 | |
| Cost of sales and operating expenses | | (460,441) | (394,062) | (1,294,263) | (1,421,778) | |
| Depreciation and amortization | | (61,177) | (50,492) | (172,650) | (144,932) | |
| Argentina gas settlement | | _ | _ | 32,500 | _ | |
| Gain on termination of terminal services agreement | | <u> </u> | _ | _ | 65,000 | |
| Operating income (loss) | | (11,524) | 82,446 | (21,573) | 239,828 | |
| Earnings of associate (note 4) | | 8,268 | 20,313 | 10,355 | 37,202 | |
| Finance costs (note 6) | | (23,389) | (16,211) | (66,248) | (54,978) | |
| Finance income and other expenses | | 1,607 | 918 | 4,595 | (5,650) | |
| Income (loss) before income taxes | | (25,038) | 87,466 | (72,871) | 216,402 | |
| Income tax recovery (expense): | | | | | | |
| Current | | (13,337) | 4,973 | (39,666) | (3,532) | |
| Deferred | | 22,881 | (15,189) | 59,430 | (21,281) | |
| | | 9,544 | (10,216) | 19,764 | (24,813) | |
| Net income (loss) | \$ | (15,494) \$ | 77,250 | \$ (53,107) \$ | 191,589 | |
| Attributable to: | | | | , | | |
| Methanex Corporation shareholders | \$ | (11,112) \$ | 78,073 | \$ (37,387) \$ | 191,307 | |
| Non-controlling interests | | (4,382) | (823) | (15,720) | 282 | |
| | \$ | (15,494) \$ | 77,250 | \$ (53,107) \$ | 191,589 | |
| Income (loss) per common share for the period attributable to Methanex Corporation shareholders | | | | | | |
| Basic net income (loss) per common share | \$ | (0.12) \$ | 0.87 | \$ (0.42) \$ | 2.10 | |
| Diluted net income (loss) per common share (note 7) | \$ | (0.12) \$ | 0.54 | \$ (0.42) \$ | 1.90 | |
| Weighted average number of common shares outstanding (note 7) | | 89,800,458 | 90,144,422 | 89,772,093 | 90,967,926 | |
| Diluted weighted average number of common shares outstanding (note 7) | | 89,800,458 | 90,692,425 | 89,772,093 | 91,755,493 | |
| Diffused weighted average number of common shares outstanding (note /) | | 09,000,430 | 30,034, 4 23 | 09,774,093 | 91,/33, 4 93 | |

Consolidated Statements of Comprehensive Income (Loss) (unaudited)

(thousands of U.S. dollars)

| | Three Months Ended | | | | Nine Months Ended | | | |
|---|---------------------------|----------------|----------------|----|-------------------|----------------|--|--|
| | | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 | | |
| Net income (loss) | \$ | (15,494) \$ | 77,250 | \$ | (53,107) \$ | 191,589 | | |
| Other comprehensive income (loss), net of taxes: | | | | | | | | |
| Items that may be reclassified to income: | | | | | | | | |
| Change in fair value of cash flow hedges (note 10) | | (1,134) | (18,822) | | 65,695 | (20,417) | | |
| Forward element excluded from hedging relationship (note 10) | | (25,370) | (9,619) | | (89,607) | (9,691) | | |
| Change in fair value of interest rate swap contracts | | _ | _ | | _ | (12) | | |
| Realized loss on interest rate swap contracts reclassified to finance costs | | _ | _ | | _ | 3,205 | | |
| Taxes on above items | | 8,754 | 9,420 | | 7,924 | 8,992 | | |
| | | (17,750) | (19,021) | | (15,988) | (17,923) | | |
| Comprehensive income (loss) | \$ | (33,244) \$ | 58,229 | \$ | (69,095) \$ | 173,666 | | |
| Attributable to: | | | | | | | | |
| Methanex Corporation shareholders | \$ | (28,862) \$ | 59,052 | \$ | (53,375) \$ | 172,266 | | |
| Non-controlling interests | | (4,382) | (823) | | (15,720) | 1,400 | | |
| | \$ | (33,244) \$ | 58,229 | \$ | (69,095) \$ | 173,666 | | |

Consolidated Statements of Financial Position (unaudited)

(thousands of U.S. dollars)

| AS AT | Sep 30 2016 | Dec 31 2015 |
|---|--------------------|----------------|
| ASSETS | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 233,677 \$ | 254,934 |
| Trade and other receivables | 412,663 | 504,350 |
| Inventories (note 2) | 247,068 | 253,234 |
| Prepaid expenses | 20,454 | 19,560 |
| | 913,862 | 1,032,078 |
| Non-current assets: | | |
| Property, plant and equipment (note 3) | 3,163,376 | 3,158,782 |
| Investment in associate (note 4) | 197,133 | 224,165 |
| Deferred income tax assets | 128,522 | 61,881 |
| Other assets | 79,884 | 79,018 |
| | 3,568,915 | 3,523,846 |
| | \$ 4,482,777 \$ | 4,555,924 |
| LIABILITIES AND EQUITY | · | |
| Current liabilities: | | |
| Trade, other payables and accrued liabilities | \$ 468,360 \$ | 508,639 |
| Current maturities on long-term debt (note 5) | 53,977 | 47,864 |
| Current maturities on other long-term liabilities | 17,606 | 25,439 |
| | 539,943 | 581,942 |
| Non-current liabilities: | | |
| Long-term debt (note 5) | 1,503,658 | 1,488,026 |
| Other long-term liabilities (note 3) | 343,833 | 231,745 |
| Deferred income tax liabilities | 286,286 | 285,638 |
| | 2,133,777 | 2,005,409 |
| Equity: | | |
| Capital stock | 510,923 | 509,464 |
| Contributed surplus | 2,576 | 2,426 |
| Retained earnings | 1,124,171 | 1,235,615 |
| Accumulated other comprehensive loss | (43,764) | (27,776) |
| Shareholders' equity | 1,593,906 | 1,719,729 |
| Non-controlling interests | 215,151 | 248,844 |
| Total equity | 1,809,057 | 1,968,573 |
| | \$ 4,482,777 \$ | 4,555,924 |

Consolidated Statements of Changes in Equity (unaudited)

(thousands of U.S. dollars, except number of common shares)

| | Number of Common Shares | Capital Stock | Contributed Surplus | Retained Earnings | Accumulated Other Comprehensive Loss | Shareholders' Equity | Non- Controlling Interests | Total Equity |
|--|-------------------------------|------------------|------------------------|----------------------|---|-------------------------|----------------------------------|-----------------|
| Balance, December 31, 2014 | 92,326,487 | \$ 521,022 | \$ 2,803 | \$1,262,961 | \$ (413) | \$ 1,786,373 | \$ 266,844 | \$ 2,053,217 |
| Net income | _ | _ | _ | 191,307 | _ | 191,307 | 282 | 191,589 |
| Other comprehensive income (loss) | _ | _ | _ | _ | (19,041) | (19,041) | 1,118 | (17,923) |
| Compensation expense recorded for stock options | _ | _ | 598 | _ | _ | 598 | _ | 598 |
| Issue of shares on exercise of stock options | 253,002 | 3,695 | _ | _ | _ | 3,695 | _ | 3,695 |
| Reclassification of grant date fair value on exercise of stock options | _ | 1,041 | (1,041) | _ | _ | - | _ | _ |
| Payments for repurchase of shares | (2,736,091) | (15,420) | _ | (122,607) | _ | (138,027) | _ | (138,027) |
| Dividend payments to Methanex Corporation shareholders | _ | _ | _ | (72,569) | _ | (72,569) | _ | (72,569) |
| Distributions made and accrued to non-controlling interests | _ | _ | _ | _ | _ | _ | (17,234) | (17,234) |
| Equity contributions by non-controlling interests | _ | _ | _ | _ | _ | _ | 500 | 500 |
| Balance, September 30, 2015 | 89,843,398 | 510,338 | 2,360 | 1,259,092 | (19,454) | 1,752,336 | 251,510 | 2,003,846 |
| Net income | _ | _ | _ | 9,310 | _ | 9,310 | 1,454 | 10,764 |
| Other comprehensive loss | _ | _ | _ | (1,063) | (8,322) | (9,385) | _ | (9,385) |
| Compensation expense recorded for stock options | _ | _ | 144 | _ | _ | 144 | _ | 144 |
| Issue of shares on exercise of stock options | 37,800 | 232 | _ | _ | _ | 232 | _ | 232 |
| Reclassification of grant date fair value on exercise of stock options | _ | 78 | (78) | _ | _ | _ | _ | _ |
| Payments for repurchase of shares | (210,000) | (1,184) | _ | (7,072) | _ | (8,256) | _ | (8,256) |
| Dividend payments to Methanex Corporation shareholders | _ | _ | _ | (24,652) | _ | (24,652) | _ | (24,652) |
| Distributions made and accrued to non-controlling interests | _ | _ | _ | _ | _ | _ | (5,320) | (5,320) |
| Equity contributions by non-controlling interests | _ | _ | _ | _ | _ | _ | 1,200 | 1,200 |
| Balance, December 31, 2015 | 89,671,198 | 509,464 | 2,426 | 1,235,615 | (27,776) | 1,719,729 | 248,844 | 1,968,573 |
| Net loss | _ | _ | _ | (37,387) | _ | (37,387) | (15,720) | (53,107) |
| Other comprehensive loss | _ | _ | _ | _ | (15,988) | (15,988) | _ | (15,988) |
| Compensation expense recorded for stock options | _ | _ | 509 | _ | _ | 509 | _ | 509 |
| Issue of shares on exercise of stock options | 137,040 | 1,100 | _ | _ | _ | 1,100 | _ | 1,100 |
| Reclassification of grant date fair value on exercise of stock options | _ | 359 | (359) | _ | _ | _ | _ | _ |
| Dividend payments to Methanex Corporation shareholders | _ | _ | _ | (74,057) | _ | (74,057) | _ | (74,057) |
| Distributions made and accrued to non-controlling interests | _ | _ | _ | _ | _ | _ | (18,498) | (18,498) |
| Equity contributions by non-controlling interests | _ | _ | _ | _ | _ | _ | 525 | 525 |
| Balance, September 30, 2016 | 89,808,238 | \$ 510,923 | \$ 2,576 | \$1,124,171 | \$ (43,764) | \$ 1,593,906 | \$ 215,151 | \$ 1,809,057 |

Consolidated Statements of Cash Flows (unaudited)

(thousands of U.S. dollars)

| | Three Months Ended | | | | Nine Months Ended | | |
|--|--------------------|----------------|----------------|----|-------------------|----------------|--|
| | | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 | |
| CASH FLOWS FROM / (USED IN) OPERATING ACTIVITIES | | , | | | | | |
| Net income (loss) | \$ | (15,494) \$ | 77,250 | \$ | (53,107) \$ | 191,589 | |
| Deduct earnings of associate | | (8,268) | (20,313) | | (10,355) | (37,202) | |
| Dividends received from associate | | 6,310 | 12,620 | | 37,860 | 56,790 | |
| Add (deduct) non-cash items: | | | | | | | |
| Depreciation and amortization | | 61,177 | 50,492 | | 172,650 | 144,932 | |
| Income tax expense (recovery) | | (9,544) | 10,216 | | (19,764) | 24,813 | |
| Share-based compensation expense (recovery) | | 13,265 | (64,440) | | 12,613 | (32,488 | |
| Finance costs | | 23,389 | 16,211 | | 66,248 | 54,978 | |
| Other | | 429 | (146) | | 2,558 | 186 | |
| Income taxes (paid) refunded | | 2,296 | (4,978) | | 212 | (39,112 | |
| Other cash payments, including share-based compensation | | (1,663) | (880) | | (19,327) | (15,051 | |
| Cash flows from operating activities before undernoted | | 71,897 | 76,032 | | 189,588 | 349,435 | |
| Changes in non-cash working capital (note 9) | | 2,033 | 57,749 | | (11,883) | (96,443 | |
| | | 73,930 | 133,781 | | 177,705 | 252,992 | |
| | | <u> </u> | | | <u> </u> | • | |
| CASH FLOWS FROM / (USED IN) FINANCING ACTIVITIES | | | | | | | |
| Payments for repurchase of shares | | _ | (27,042) | | _ | (138,027 | |
| Dividend payments to Methanex Corporation shareholders | | (24,658) | (24,750) | | (74,057) | (72,569 | |
| Interest paid | | (12,637) | (10,554) | | (51,373) | (58,495 | |
| Net proceeds on issue of long-term debt | | 26,100 | _ | | 65,700 | _ | |
| Repayment of long-term debt | | (23,345) | (21,430) | | (46,329) | (193,083 | |
| Finance leases | | (1,443) | (772) | | (3,800) | (3,330 | |
| Equity contributions by non-controlling interests | | _ | 200 | | 525 | 500 | |
| Distributions to non-controlling interests | | (910) | (1,660) | | (1,410) | (2,570 | |
| Proceeds on issue of shares on exercise of stock options | | 302 | 79 | | 1,100 | 3,695 | |
| Changes in non-cash working capital related to financing activities (note 9) | | (5,934) | (5,835) | | (17,088) | (13,670 | |
| (note s) | | (42,525) | (91,764) | | (126,732) | (477,549 | |
| | | (12,323) | (31), (31) | _ | (120), 32) | (177,313 | |
| CASH FLOWS FROM / (USED IN) INVESTING ACTIVITIES | | | | | | | |
| Property, plant and equipment | | (28,331) | (24,620) | | (89,638) | (87,231 | |
| Geismar plants under construction | | (20,331) | (72,778) | | (05,050) | (243,669 | |
| Termination of terminal services agreement | | _ | | | - | 65,000 | |
| Other assets | | _ | _ | | (66) | | |
| Changes in non-cash working capital related to investing activities | | _ | | | (66) | 1,996 | |
| (note 9) | | (8,367) | (2,622) | | 17,474 | (36,431 | |
| | | (36,698) | (100,020) | | (72,230) | (300,335 | |
| Decrease in cash and cash equivalents | | (5,293) | (58,003) | | (21,257) | (524,892 | |
| Cash and cash equivalents, beginning of period | | 238,970 | 484,711 | | 254,934 | 951,600 | |
| Cash and cash equivalents, end of period | \$ | 233,677 \$ | 426,708 | \$ | 233,677 \$ | 426,708 | |

Notes to Condensed Consolidated Interim Financial Statements (unaudited)

Except where otherwise noted, tabular dollar amounts are stated in thousands of U.S. dollars.

1. Basis of presentation:

Methanex Corporation ("the Company") is an incorporated entity with corporate offices in Vancouver, Canada. The Company's operations consist of the production and sale of methanol, a commodity chemical. The Company is the world's largest producer and supplier of methanol to the major international markets of Asia Pacific, North America, Europe and South America.

These condensed consolidated interim financial statements are prepared in accordance with *International Accounting Standards* ("IAS") 34, *Interim Financial Reporting*, as issued by the International Accounting Standards Board ("IASB") on a basis consistent with those followed in the most recent annual consolidated financial statements.

These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and were approved and authorized for issue by the Audit, Finance & Risk Committee of the Board of Directors on October 26, 2016.

These condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements for the year ended December 31, 2015.

Certain comparative figures in the consolidated statements of financial position have been reclassified to conform to the current period's presentation.

2. Inventories:

Inventories are valued at the lower of cost, determined on a first-in first-out basis, and estimated net realizable value. The amount of inventories included in cost of sales and operating expenses and depreciation and amortization for the three and nine month periods ended September 30, 2016 is \$439 million (2015 - \$459 million) and \$1,251 million (2015 - \$1,421 million), respectively.

3. Property, plant and equipment:

| | ildings, Plant nstallations & Machinery | F | inance Leases | Other | Total |
|--|---|----|---------------|------------|-----------------|
| Cost at September 30, 2016 | \$ 4,539,765 | \$ | 206,260 | \$ 271,301 | \$ 5,017,326 |
| Accumulated depreciation at September 30, 2016 | 1,702,130 | | 14,565 | 137,255 | 1,853,950 |
| Net book value at September 30, 2016 | \$ 2,837,635 | \$ | 191,695 | \$ 134,046 | \$ 3,163,376 |
| Cost at December 31, 2015 | \$ 4,521,835 | \$ | 121,849 | \$ 204,483 | \$ 4,848,167 |
| Accumulated depreciation at December 31, 2015 | 1,545,834 | | 6,853 | 136,698 | 1,689,385 |
| Net book value at December 31, 2015 | \$ 2,976,001 | \$ | 114,996 | \$ 67,785 | \$ 3,158,782 |

During the nine months ended September 30, 2016, the Company took delivery of four new ocean going vessels which are included in property, plant and equipment. Two of the vessels are accounted for as finance leases, with offsetting finance lease obligations recorded in other long-term liabilities, and two are owned through less than wholly-owned entities under the Company's control and included in "Other".

4. Interest in Atlas joint venture:

a) The Company has a 63.1% equity interest in Atlas Methanol Company Unlimited ("Atlas"). Atlas owns a 1.8 million tonne per year methanol production facility in Trinidad. The Company accounts for its interest in Atlas using the equity method. Summarized financial information of Atlas (100% basis) is as follows:

| Consolidated statements of financial position as at | Sep 30 2016 | Dec 31 2015 |
|---|------------------|----------------|
| Cash and cash equivalents | \$ 6,978 \$ | 57,620 |
| Other current assets | 46,438 | 45,854 |
| Non-current assets | 333,094 | 332,072 |
| Current liabilities | (26,695) | (30,440) |
| Other long-term liabilities, including current maturities | (167,980) | (169,681) |
| Net assets at 100% | 191,835 | 235,425 |
| Net assets at 63.1% | 121,048 | 148,553 |
| Long-term receivable from Atlas | 76,085 | 75,612 |
| Investment in associate | \$ 197,133 \$ | 224,165 |

| | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------|----------------|----|-------------------|----------------|--|
| Consolidated statements of income | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 | |
| Revenue | \$ 80,247 \$ | 95,285 | \$ | 148,224 \$ | 277,919 | |
| Cost of sales and depreciation and amortization | (56,646) | (42,463) | | (108,066) | (178,747) | |
| Operating income | 23,601 | 52,822 | | 40,158 | 99,172 | |
| Finance costs, finance income and other expenses | (3,418) | (2,273) | | (9,998) | (6,967) | |
| Income tax expense | (7,080) | (18,358) | | (13,750) | (33,248) | |
| Net earnings at 100% | 13,103 | 32,191 | | 16,410 | 58,957 | |
| Earnings of associate at 63.1% | 8,268 | 20,313 | | 10,355 | 37,202 | |
| | | | | | | |
| Dividends received from associate | \$ 6,310 \$ | 12,620 | \$ | 37,860 \$ | 56,790 | |

b) Contingent liability:

The Board of Inland Revenue of Trinidad and Tobago has issued assessments against Atlas in respect of the 2005, 2006, 2007, 2008, and 2009 financial years. All subsequent tax years remain open to assessment. The assessments relate to the pricing arrangements of certain long-term fixed price sales contracts from 2005 to 2019 related to methanol produced by Atlas. Atlas had partial relief from corporation income tax until late July 2014.

The Company has lodged objections to the assessments. Based on the merits of the cases and legal interpretation, management believes its position should be sustained.

5. Long-term debt:

| As at | Sep 30 2016 | Dec 31 2015 |
|--|--------------------|----------------|
| Unsecured notes | | |
| \$350 million at 3.25% due December 15, 2019 | \$ 346,953 \$ | 346,289 |
| \$250 million at 5.25% due March 1, 2022 | 247,627 | 247,360 |
| \$300 million at 4.25% due December 1, 2024 | 296,458 | 296,219 |
| \$300 million at 5.65% due December 1, 2044 | 295,078 | 295,031 |
| | 1,186,116 | 1,184,899 |
| Egypt limited recourse debt facilities | 288,164 | 330,003 |
| Other limited recourse debt facilities | 83,355 | 20,988 |
| Total long-term debt ¹ | 1,557,635 | 1,535,890 |
| Less current maturities | (53,977) | (47,864) |
| | \$ 1,503,658 \$ | 1,488,026 |

¹ Long-term debt is presented net of deferred financing fees.

During the nine months ended September 30, 2016, the Company made repayments on its Egypt limited recourse debt facilities of \$43.0 million, drew down \$65.7 million on its other limited recourse debt facilities and made repayments of \$3.3 million on its other limited recourse debt facilities. Other limited recourse debt facilities relates to financing for certain of our ocean going vessels which we own through less than wholly-owned entities under the Company's control.

The Company maintains a \$300 million committed revolving credit facility with a syndicate of highly rated financial institutions that expires in December 2019. During the second quarter of 2016, the Company amended the credit facility to allow for relief, if required, of the interest coverage ratio covenant through the end of 2017. Significant covenant and default provisions of the facility include:

a) the obligation to maintain an EBITDA to interest coverage ratio of greater than 2:1 calculated on a four-quarter trailing basis and a debt to capitalization ratio of less than or equal to 55%, both ratios calculated in accordance with definitions in the credit agreement that include adjustments to the limited recourse subsidiaries,

b) a default if payment is accelerated by a creditor on any indebtedness of \$50 million or more of the Company and its subsidiaries, except for the limited recourse subsidiaries, and

c) a default if a default occurs that permits a creditor to demand repayment on any other indebtedness of \$50 million or more of the Company and its subsidiaries, except for the limited recourse subsidiaries.

The Egypt limited recourse debt facilities have covenants and default provisions that apply only to the Egypt entity, including restrictions on the incurrence of additional indebtedness and a requirement to fulfill certain conditions before the payment of cash or other shareholder distributions. Certain conditions have not been met, resulting in a restriction on shareholder distributions from the Egypt entity. As of September 30, 2016, the Egypt cash balance on a 100% ownership basis was \$50 million. The Egypt entity continues to be able to fully utilize its funds for operating, capital and financing needs, including the repayment of the Egypt limited recourse debt facilities.

At September 30, 2016, management believes the Company was in compliance with all significant terms and default provisions related to long-term debt obligations.

6. Finance costs:

| | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------|----------------|----------------|-------------------|----------------|----------------|
| | | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 |
| Finance costs | \$ | 23,389 \$ | 21,283 | \$ | 66,248 \$ | 69,891 |
| Less capitalized interest related to Geismar plants under construction | | _ | (5,072) | | _ | (14,913) |
| | \$ | 23,389 \$ | 16,211 | \$ | 66,248 \$ | 54,978 |

Finance costs are primarily comprised of interest on borrowings and finance lease obligations, amortization of deferred financing fees, finance costs related to finance leases, and accretion expense associated with site restoration costs. Capitalized interest relates to interest costs capitalized for the Geismar project which was completed in 2015.

7. Net income (loss) per common share:

Diluted net income (loss) per common share is calculated by considering the potential dilution that would occur if outstanding stock options and, under certain circumstances, tandem share appreciation rights ("TSARs") were exercised or converted to common shares.

Outstanding TSARs may be settled in cash or common shares at the holder's option and for purposes of calculating diluted net income (loss) per common share, the more dilutive of the cash-settled and equity-settled method is used, regardless of how the plan is accounted for. Accordingly, TSARs that are accounted for using the cash-settled method will require adjustments to the numerator and denominator if the equity-settled method is determined to have a dilutive effect on diluted net income (loss) per common share as compared to the cash-settled method. For the three and nine months ended September 30, 2016, the cash-settled method was more dilutive for TSARs and no adjustment was required for the numerator or the denominator. For the same periods in 2015, the equity-settled method was more dilutive, so an adjustment was required for both the numerator and the denominator.

For the three and nine months ended September 30, 2016, the Company incurred a net loss attributable to Methanex shareholders and therefore exclusion of the stock options was more dilutive, so no adjustment was made to the denominator. For the same periods in 2015, stock options were considered dilutive when the average market price of the Company's common shares during the period disclosed exceeded the exercise price of the stock option, so an adjustment was made to the denominator.

A reconciliation of the numerator used for the purpose of calculating diluted net income (loss) per common share is as follows:

| | Three Months Ended | | | Nine Months Ended | | |
|--|--------------------|----------------|----------------|-------------------|----------------|----------------|
| | | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 |
| Numerator for basic net income (loss) per common share | \$ | (11,112) \$ | 78,073 | \$ | (37,387) \$ | 191,307 |
| Adjustment for the effect of TSARs: | | | | | | |
| Cash-settled recovery included in net income | | _ | (28,772) | | _ | (12,507) |
| Equity-settled expense | | _ | (700) | | _ | (4,612) |
| Numerator for diluted net income (loss) per common share | \$ | (11,112) \$ | 48,601 | \$ | (37,387) \$ | 174,188 |

7. Net income (loss) per common share (continued):

A reconciliation of the denominator used for the purposes of calculating basic and diluted net income (loss) per common share is as follows:

| | Three Montl | ns Ended | Nine Months Ended | | |
|--|----------------|----------------|-------------------|----------------|--|
| | Sep 30 2016 | Sep 30 2015 | Sep 30 2016 | Sep 30 2015 | |
| Denominator for basic net income (loss) per common share | 89,800,458 | 90,144,422 | 89,772,093 | 90,967,926 | |
| Effect of dilutive stock options | _ | 211,859 | _ | 306,365 | |
| Effect of dilutive TSARs | _ | 336,144 | | 481,202 | |
| Denominator for diluted net income (loss) per common share | 89,800,458 | 90,692,425 | 89,772,093 | 91,755,493 | |

8. Share-based compensation:

a) Share appreciation rights ("SARs"), TSARs and stock options:

(i) Outstanding units:

Information regarding units outstanding at September 30, 2016 is as follows:

| | SAR | s | TSARs | | | |
|-----------------------------------|-----------------|------------------------------------|-----------------|------------------------------------|--|--|
| (per share amounts in USD) | Number of Units | Veighted Average Exercise Price | Number of Units | Weighted Average Exercise Price | | |
| Outstanding at December 31, 2015 | 1,259,208 \$ | 44.48 | 2,108,965 | \$ 42.73 | | |
| Granted | 375,500 | 34.59 | 574,600 | 34.59 | | |
| Exercised | (7,091) | 27.32 | (4,800) | 26.54 | | |
| Cancelled | (17,321) | 53.97 | (37,400) | 56.12 | | |
| Outstanding at June 30, 2016 | 1,610,296 \$ | 42.15 | 2,641,365 | \$ 40.80 | | |
| Exercised | (4,050) | 27.57 | (15,300) | 25.70 | | |
| Cancelled | (5,540) | 53.92 | (17,549) | 44.93 | | |
| Outstanding at September 30, 2016 | 1,600,706 \$ | 42.15 | 2,608,516 | \$ 40.86 | | |

| | Stock Opt | Stock Options | | | | |
|-----------------------------------|-----------------|-----------------------------------|--|--|--|--|
| (per share amounts in USD) | Number of Units | eighted Average Exercise Price | | | | |
| Outstanding at December 31, 2015 | 448,507 \$ | 30.52 | | | | |
| Granted | 75,500 | 34.59 | | | | |
| Exercised | (125,040) | 6.33 | | | | |
| Cancelled | (1,800) | 55.66 | | | | |
| Expired | (12,000) | 6.33 | | | | |
| Outstanding at June 30, 2016 | 385,167 \$ | 39.81 | | | | |
| Exercised | (12,000) | 25.22 | | | | |
| Cancelled | (10,600) | 43.58 | | | | |
| Outstanding at September 30, 2016 | 362,567 \$ | 40.18 | | | | |

8. Share-based compensation (continued):

a) Share appreciation rights ("SARs"), TSARs and stock options (continued):

(i) Outstanding units (continued):

| | Units Outsta | nding at Septem | oer 30, 2016 | | Units Exercisable at | nits Exercisable at September 30, 2 | | |
|--|--|-----------------------------------|--------------------------------|----|--------------------------------|-------------------------------------|---------------------------------------|--|
| Range of Exercise Prices (per share amounts in USD) | Weighted Average Remaining Contractual Life (Years) | Number of Units Outstanding | Weight Avera Exercise Pr | ge | Number of Units Exercisable | | Weighted Average Exercise Price | |
| SARs: | | | | | | | | |
| \$23.36 to \$40.72 | 3.72 | 1,121,779 | \$ 33. | 35 | 744,646 | \$ | 32.70 | |
| \$46.42 to \$73.13 | 5.01 | 478,927 | 62. | 74 | 226,676 | | 65.61 | |
| | 4.11 | 1,600,706 | \$ 42. | 15 | 971,322 | \$ | 40.38 | |
| TSARs: | | | | | | | | |
| \$23.36 to \$40.72 | 3.50 | 1,930,537 | \$ 33. | 11 | 1,360,037 | \$ | 32.49 | |
| \$46.42 to \$73.13 | 5.01 | 677,979 | 62. | 92 | 319,843 | | 65.92 | |
| | 3.90 | 2,608,516 | \$ 40. | 86 | 1,679,880 | \$ | 38.86 | |
| Stock options: | | | | | | | | |
| \$6.33 to \$25.22 | 0.42 | 37,750 | \$ 25. | 22 | 37,750 | \$ | 25.22 | |
| \$28.43 to \$73.13 | 4.10 | 324,817 | 41. | 92 | 204,139 | | 40.26 | |
| | 3.72 | 362,567 | \$ 40. | 18 | 241,889 | \$ | 37.91 | |

(ii) Compensation expense related to SARs and TSARs:

Compensation expense for SARs and TSARs is measured based on their fair value and is recognized over the vesting period. Changes in fair value each period are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value at September 30, 2016 was \$26.1 million compared with the recorded liability of \$22.8 million. The difference between the fair value and the recorded liability of \$3.3 million will be recognized over the weighted average remaining vesting period of approximately 1.67 years. The weighted average fair value was estimated at September 30, 2016 using the Black-Scholes option pricing model.

For the three and nine month periods ended September 30, 2016, compensation expense related to SARs and TSARs included an expense in cost of sales and operating expenses of \$10.9 million (2015 - recovery of \$44.6 million) and an expense of \$9.8 million (2015 - recovery of \$19.6 million), respectively. This included an expense of \$10.0 million (2015 - recovery of \$45.3 million) and an expense of \$3.8 million (2015 - recovery of \$26.8 million), respectively, related to the effect of the change in the Company's share price for the three and nine months ended September 30, 2016.

(iii) Compensation expense related to stock options:

For the three and nine month periods ended September 30, 2016, compensation expense related to stock options included in cost of sales and operating expenses was \$0.1 million (2015 - \$0.2 million) and \$0.5 million (2015 - \$0.6 million), respectively. The fair value of each stock option grant was estimated on the grant date using the Black-Scholes option pricing model.

8. Share-based compensation (continued):

b) Deferred, restricted and performance share units:

Deferred, restricted and performance share units outstanding at September 30, 2016 are as follows:

| | Number of Deferred Share Units | Number of Restricted Share Units | Number of Performances Share Units |
|---|-----------------------------------|-------------------------------------|---------------------------------------|
| Outstanding at December 31, 2015 | 285,816 | 13,864 | 610,578 |
| Granted | 7,011 | 11,500 | 261,760 |
| Granted performance factor ¹ | _ | _ | 55,592 |
| Granted in-lieu of dividends | 4,892 | 433 | 9,646 |
| Redeemed | (41,498) | _ | (355,415) |
| Cancelled | _ | _ | (11,855) |
| Outstanding at June 30, 2016 | 256,221 | 25,797 | 570,306 |
| Granted | 673 | | _ |
| Granted in-lieu of dividends | 1,979 | 225 | 4,933 |
| Cancelled | _ | _ | (5,851) |
| Outstanding at September 30, 2016 | 258,873 | 26,022 | 569,388 |

Performance share units have a feature where the ultimate number of units that vest are adjusted by a performance factor of the original grant as determined by the Company's total shareholder return in relation to a predetermined target over the period to vesting. These units relate to performance share units redeemed in the quarter ended March 31, 2016.

Compensation expense for deferred, restricted and performance share units is measured at fair value based on the market value of the Company's common shares and is recognized over the vesting period. Changes in fair value are recognized in net income for the proportion of the service that has been rendered at each reporting date. The fair value of deferred, restricted and performance share units at September 30, 2016 was \$15.6 million compared with the recorded liability of \$13.9 million. The difference between the fair value and the recorded liability of \$1.7 million will be recognized over the weighted average remaining vesting period of approximately 1.70 years.

For the three and nine month periods ended September 30, 2016, compensation expense related to deferred, restricted and performance share units included in cost of sales and operating expenses was an expense of \$2.1 million (2015 - recovery of \$19.9 million) and an expense of \$2.4 million (2015 - recovery of \$13.5 million), respectively. This included an expense of \$1.6 million (2015 - recovery of \$21.7 million) and a recovery of \$0.2 million (2015 - recovery of \$22.0 million) related to the effect of the change in the Company's share price for the three and nine month periods ended September 30, 2016.

9. Changes in non-cash working capital:

Changes in non-cash working capital for the three and nine month periods ended September 30, 2016 and 2015 were as follows:

| | Three Months Ended | | | | Nine Months Ended | | |
|--|--------------------|----------------|----------------|----|-------------------|----------------|--|
| | | Sep 30 2016 | Sep 30 2015 | | Sep 30 2016 | Sep 30 2015 | |
| Changes in non-cash working capital: | | | | | | | |
| Trade and other receivables | \$ | (6,808) \$ | 81,523 | \$ | 91,687 \$ | (60,647) | |
| Inventories | | 6,638 | 46,983 | | 6,166 | 37,716 | |
| Prepaid expenses | | (677) | (6,361) | | (894) | 2,469 | |
| Trade, other payables and accrued liabilities | | 24,108 | (67,191) | | (40,279) | (66,879) | |
| | | 23,261 | 54,954 | | 56,680 | (87,341) | |
| Adjustments for items not having a cash effect and working capital changes relating to taxes and interest paid | | (35,529) | (5,662) | | (68,177) | (59,203) | |
| Changes in non-cash working capital having a cash effect | \$ | (12,268) \$ | 49,292 | \$ | (11,497) \$ | (146,544) | |
| These changes relate to the following activities: | | | | | | | |
| Operating | \$ | 2,033 \$ | 57,749 | \$ | (11,883) \$ | (96,443) | |
| Financing | | (5,934) | (5,835) | | (17,088) | (13,670) | |
| Investing | | (8,367) | (2,622) | | 17,474 | (36,431) | |
| Changes in non-cash working capital | \$ | (12,268) \$ | 49,292 | \$ | (11,497) \$ | (146,544) | |

10. Financial instruments:

Financial instruments are either measured at amortized cost or fair value.

In the normal course of business, the Company's assets, liabilities and forecasted transactions, as reported in U.S. dollars, are impacted by various market risks including, but not limited to, natural gas prices and currency exchange rates. The time frame and manner in which the Company manages those risks varies for each item based on the Company's assessment of the risk and the available alternatives for mitigating risks.

The Company uses derivatives as part of its risk management program to mitigate variability associated with changing market values. Changes in fair value of derivative financial instruments are recorded in earnings unless the instruments are designated as cash flow hedges. The Company designates as cash flow hedges derivative financial instruments to hedge its risk exposure to fluctuations in the euro compared to the U.S. dollar and derivative financial instruments to hedge its risk exposure to fluctuations in natural gas prices.

The fair value of derivative instruments is determined based on industry-accepted valuation models using market observable inputs and are classified within Level 2 of the fair value hierarchy. The fair value of all of the Company's derivative contracts includes an adjustment for credit risk. The effective portion of the changes in fair value of derivative financial instruments designated as cash flow hedges is recorded in other comprehensive income. The spot element of forward contracts in the hedging relationships is recorded in other comprehensive income as the change in fair value of cash flow hedges. The change in the fair value of the forward element of forward contracts is recorded separately in other comprehensive income as the forward element excluded from hedging relationship.

10. Financial instruments (continued):

Natural gas forward contracts

The Company has elected to manage its exposure to changes in natural gas prices for the Geismar 2 facility by executing a number of forward contracts which it has designated as cash flow hedges for its highly probable forecast natural gas purchases in North America.

As at September 30, 2016, the Company had outstanding forward contracts designated as cash flow hedges with a notional amount of \$495 million (December 31, 2015 - \$517 million) and a negative fair value of \$64.9 million (December 31, 2015 - \$42.7 million) included in other long-term liabilities.

Euro forward exchange contracts

The Company manages its foreign currency exposure to euro denominated sales by executing a number of forward contracts which it has designated as cash flow hedges for its highly probable forecast euro collections.

As at September 30, 2016, the Company had outstanding forward exchange contracts designated as cash flow hedges to sell a notional amount of 69 million euros (December 31, 2015 - 35 million euros). The euro contracts had a negative fair value of \$0.5 million recorded in current liabilities at September 30, 2016 (December 31, 2015 - positive \$1.2 million recorded in current assets).

The fair value of the Company's derivative financial instruments as disclosed above are determined based on Bloomberg quoted market prices and confirmations received from counterparties, which are adjusted for credit risk.

The table below shows net cash flows for derivative hedging instruments, excluding credit risk adjustments, based upon contracted settlement dates. The amounts reflect the maturity profile of the hedging instruments and are subject to change based on the prevailing market rate at each of the future settlement dates. Financial asset derivative positions are held with investment-grade counterparties and therefore the settlement day risk exposure is considered to be negligible.

| | Cash inflows (outflows) by term to maturity | | | | | | | |
|---------------------------------|---|-----------|-----------|----------------------|----------|--|--|--|
| | 1 year or less | 1-3 years | 3-5 years | More than 5 years | Total | | | |
| Natural gas forward contracts | (927) | (11,030) | (18,615) | (44,953) \$ | (75,525) | | | |
| Euro forward exchange contracts | (210) | _ | _ | - \$ | (210) | | | |

The carrying values of the Company's financial instruments approximate their fair values, except as follows:

| | | September 30, 2016 | | |
|--|-----|------------------------|-----------|--|
| As at | Cai | Carrying Value Fair Va | | |
| Long-term debt excluding deferred financing fees | \$ | 1,570,780 \$ | 1,527,405 | |

Long-term debt consists of limited recourse debt facilities and unsecured notes. There is no publicly traded market for the limited recourse debt facilities. The fair value of the limited recourse debt facilities as disclosed on a recurring basis and categorized as Level 2 within the fair value hierarchy is estimated by reference to current market rates as at the reporting date. The fair value of the unsecured notes disclosed on a recurring basis and also categorized as Level 2 within the fair value hierarchy was estimated using quoted prices and yields as at the reporting date. The fair value of the Company's long term debt will fluctuate until maturity.

Methanex Corporation Quarterly History (unaudited)

| | 2016 | Q3 | Q2 | Q1 | 2015 | Q4 | Q3 | Q2 | Q1 |
|--|--------|--------|--------|--------|-------|-------|-------|-------|-------|
| | | | | | | | | | |
| METHANOL SALES VOLUME | | | | | | | | | |
| (thousands of tonnes) | | | | | | | | | |
| | | | | | | | | | |
| Methanex-produced ¹ | 5,078 | 1,860 | 1,689 | 1,529 | 5,050 | 1,372 | 1,238 | 1,203 | 1,237 |
| Purchased methanol | 1,366 | 411 | 533 | 422 | 2,780 | 636 | 679 | 813 | 652 |
| Commission sales ¹ | 513 | 205 | 140 | 168 | 641 | 178 | 169 | 109 | 185 |
| | 6,957 | 2,476 | 2,362 | 2,119 | 8,471 | 2,186 | 2,086 | 2,125 | 2,074 |
| METHANOL PRODUCTION | | | | | | | | | |
| (thousands of tonnes) | | | | | | | | | |
| | | | | | | | | | |
| New Zealand | 1,645 | 559 | 577 | 509 | 1,856 | 412 | 476 | 487 | 481 |
| Geismar (Louisiana, USA) | 1,529 | 519 | 527 | 483 | 959 | 244 | 259 | 276 | 180 |
| Trinidad (Methanex interest) | 1,150 | 420 | 417 | 313 | 1,644 | 432 | 398 | 419 | 395 |
| Egypt (50% interest) | 197 | 69 | 53 | 75 | 74 | 58 | _ | 8 | 8 |
| Medicine Hat (Canada) | 396 | 114 | 123 | 159 | 456 | 155 | 123 | 51 | 127 |
| Chile | 241 | 68 | 73 | 100 | 204 | 88 | 3 | 40 | 73 |
| | 5,158 | 1,749 | 1,770 | 1,639 | 5,193 | 1,389 | 1,259 | 1,281 | 1,264 |
| AVERAGE REALIZED METHANOL PRICE ² | | | | | | | | | |
| (\$/tonne) | 230 | 236 | 223 | 230 | 322 | 277 | 323 | 350 | 337 |
| (\$/gallon) | 0.69 | 0.71 | 0.67 | 0.69 | 0.97 | 0.83 | 0.97 | 1.05 | 1.01 |
| | | | | | | | | | |
| PER SHARE INFORMATION (\$ per common share attributable to Methanex shareholders) | | | | | | | | | |
| Adjusted net income (loss) | (0.63) | (0.01) | (0.34) | (0.27) | 1.20 | 0.16 | 0.26 | 0.56 | 0.23 |
| Basic net income (loss) | (0.42) | (0.12) | (0.03) | (0.26) | 2.21 | 0.10 | 0.87 | 1.15 | 0.09 |
| Diluted net income (loss) | (0.42) | (0.12) | (80.0) | (0.26) | 2.01 | 0.10 | 0.54 | 1.15 | 0.09 |

¹ Methanex-produced methanol includes any volume produced by Chile using natural gas supplied from Argentina under a tolling arrangement. Commission sales represent volume marketed on a commission basis related to the 36.9% of the Atlas methanol facility and 50% of the Egypt methanol facility that we do not own.

² Average realized price is calculated as revenue, excluding commissions earned and the Egypt non-controlling interest share of revenue, but including an amount representing our share of Atlas revenue, divided by the total sales volume of Methanex-produced (attributable to Methanex shareholders) and purchased methanol, but excluding Tolling Volume.